TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00003516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
Study: NCT00307463

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: strict volume control policy
Description: strict volume control by UF and dietary salt restriction

Intervention type: PROCEDURE
Group type: OTHER
Intervention: antihypertensive drugs administration
Description: continue antihypertensive medications
Study: NCT02613871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT01272427

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with noncaloric sweetener
Description: 0.15 g of sucralose added to water
Study: NCT00959582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparator: 18-F-FDG PET/CT and Volumetric CT
Description: Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing.
Study: NCT02296424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885 150 mg (Canakinumab)
Description: Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885 150 mg (Canakinumab)
Description: Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
Study: NCT03901937

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ω-3 polyunsaturated fatty acid
Description: CD patients are divided into two groups, which include with and without ω-3 polyunsaturated fatty acid-based PN (0.1-0.2g/kg/d).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intestinal surgery for Crohn's Disease
Description: Patients receive bowel resection due to complications of Crohn's Disease
Study: NCT00111358

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No lifestyle modification
Study: NCT03269799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C 500 MG Oral Capsule
Description: non surgical periodontal treatment+vitamin C 500 mg/day for 2 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: non surgical periodontal treatment+placebo for 2 months
Study: NCT01766791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT-exercise, low repetition range
Description: High Intensity Resistance Exercise Training, low repetition range, \> 75% 1RM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT-exercise, high repetition range
Description: High Intensity Resistance Exercise Training, high repetition range, 60 - \< 75 1RM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT-exercise with protein
Description: High Intensity Resistance Exercise Training, low repetition range, \> 75% 1RM and Protein Supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: control group, no intervention, maintenance of physical activity
Study: NCT02229565

Intervention type: DEVICE
Intervention: Biopsy or prostatectomy

Intervention type: DEVICE
Intervention: Biopsy or prostatectomy
Study: NCT01612884

Intervention type: DRUG
Group type: OTHER
Intervention: Prasugrel
Description: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder

Intervention type: DRUG
Group type: OTHER
Intervention: Prasugrel
Description: Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder
Study: NCT02668094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study: NCT00908557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: readability improvement and good practice redaction
Description: improvement using Flesch readability index and good practice in redaction of informed consent documents.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: information based on the classic informed consent document
Study: NCT01099488

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood withdrawal
Description: Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received GSK2231392A vaccine, were enrolled for blood withdrawal, at each study visit: Day 0, Day 14 and Day 180, to support the development of CD8+ T cell immunological detection assays.
Study: NCT03276442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Description: Low-fat diet (5-7 days) preceding extended wakefulness under standardized conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat dietary intervention
Description: High-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
Study: NCT04546789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951 (BTK inhibitor)
Description: Participants will receive a single oral dose of M2951 (BTK inhibitor).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951 (BTK inhibitor)
Description: Participants will receive a single oral dose of M2951 (BTK inhibitor).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951 (BTK inhibitor)
Description: Participants will receive a single oral dose of M2951 (BTK inhibitor).
Study: NCT00791648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1.
Study: NCT03901937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intestinal surgery for Crohn's Disease
Description: Patients receive bowel resection due to complications of Crohn's Disease
Study: NCT03565523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beetroot
Description: Containing 385 mg nitrate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: \<0.1 mmol nitrate in sucrose solution with beet coloring
Study: NCT04670159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Education
Description: Online ergonomics, exercise and physical activity training will be provided 3 times a week for 6 weeks. The trainings it is planned to be made with a video-based online platform called Edpuzzle. With the online classroom created, the student education will be provided. A total of 18 training videos will be prepared, each video is 6-10 minutes. After the training there will be an individual motivational interview with the students in the this group with the zoom application. With motivational interview solutions by revealing the willingness, obstacles and indecision of the student to transfer the learned information to his daily life will be recommended.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information With Brochure
Description: An e-brochure will be prepared for students in this group to provide information on ergonomics, physical activity and exercise. and the e-brochure will be sent to the students via e-mail after the initial evaluation.
Study: NCT02327611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Ringer's lactate solution
Study: NCT00617812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shan5
Description: Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
Study: NCT03754218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amnion Membrane Powder
Description: This sterilized product is composed of lyophilized, gamma-irradiated powder made from amniotic membrane for topical application with the purpose of enhanced wound healing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SOC Wound Covering
Description: Institutional standard of care wound covering.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOC Wound Covering
Description: Institutional standard of care wound covering.
Study: NCT01965119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
Study: NCT02682446

Intervention type: DRUG
Intervention: H pylori eradication
Description: The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen \[lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week\]

Intervention type: DRUG
Intervention: H pylori eradication
Description: The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen \[lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week\]
Study: NCT03131206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: * Oral, BID~* Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~* Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: * Oral, BID~* Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~* Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: * Oral, BID~* Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~* Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: * Oral, BID~* Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~* Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days.
Study: NCT02960269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interprofessional back pain assessment
Description: team assessment and education with urban physical therapist and rural nurse practitioner via telehealth
Study: NCT00860353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2551
Description: Single dose of oral solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of oral solution
Study: NCT03342560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonographic SWE measurements with 4 different ultrasound systems
Description: Sonographic Shear wave elastography will be performed to quantify liver fibrosis
Study: NCT02665260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cantharidin
Description: cantharidin 0.7% topical liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: cantharidin 0.7% topical liquid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical liquid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical liquid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze occlusion bandage
Description: Gauze occlusion bandage with adhesive tape

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Gauze occlusion bandage
Description: Gauze occlusion bandage with adhesive tape
Study: NCT04068805

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
Study: NCT04747392

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: SAL001
Description: administrated once by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: SAL001
Description: administrated once by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FORSTEO
Description: administrated once by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FORSTEO
Description: administrated once by subcutaneous injection
Study: NCT03923491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Feeding, Healthy Eating
Description: Home Based Motivational Interviewing to Improve Diet Quality of Preschoolers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading Readiness
Description: Active Control that uses Motivational Interviewing to improve Reading Readiness of Preschool Children
Study: NCT02433795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine plus rituximab
Description: Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle
Study: NCT03499236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Wave Interatrial Shunt
Description: The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovalis and straddles the interatrial septum.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Wave Interatrial Shunt
Description: The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovalis and straddles the interatrial septum.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Right heart catheterization, invasive echocardiography.
Study: NCT04105868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Participants will receive feedback during a computerized task that is based on their own visuocortical activity evoked by attention to negative distractors and task-relevant stimuli on the computer screen.
Study: NCT01221779

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intensive language therapy
Description: 2 weeks of daily computerized naming training, daily, 3 hours

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive language therapy
Description: 2 weeks of daily computerized naming training, daily, 3 hours
Study: NCT03990272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIT drops
Description: once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo drops
Description: once a day
Study: NCT04063826

Intervention type: DEVICE
Group type: OTHER
Intervention: PET MRI
Description: All participants will have a liver scan
Study: NCT01976910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM-CHOC-PEN
Description: DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued.
Study: NCT00814346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGb761®
Description: Four weeks for AD patients, 18 months for MC and CNE patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet BID
Study: NCT01886625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unilateral single-port VATS sympathicotomy
Study: NCT04551781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 Mg Prednisone for 14 days
Description: 20 Mg Prednisone for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: symptomatic ttt
Study: NCT00816049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6MPindividualized
Description: Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6MPfixed
Description: Oral 6-mercaptopurine at a fixed dose of 25 mg/m2 treatment days 30-85
Study: NCT02571387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham meditation
Study: NCT04143126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy
Description: An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Supportive Therapy
Description: An 18-month intervention that uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
Study: NCT03105219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
Study: NCT02279017

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mHealth Texting for Weight Loss
Study: NCT00587925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone Mineral Density
Description: Clinic visits twice during the first 2 years of the study with medical care directed by your treating doctor.BMD is measured by an X-ray test. The most common type of BMD testing is by energy x-ray absorptiometry (DEXA). Usually BMD is measured every other year, but to closely monitor women on this study, the BMD will be evaluated more often. The BMD will be measured 3 times (baseline, 12 months and 24 months) on this study. Study blood work is obtained three times (baseline, 6 months, and 12 months). Blood (about 3 teaspoons).
Study: NCT01806454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Study: NCT05390736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait and balance assessment
Description: Patients are given Time Up and Go (TUG) tests, 30-second chair test, and 4-stage balance test (side-by-side, instep, tandem, and one foot).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait and balance assessment
Description: Patients are given Time Up and Go (TUG) tests, 30-second chair test, and 4-stage balance test (side-by-side, instep, tandem, and one foot).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Patients' medication history in the EHR is assessed for polypharmacy (using 5 or more medications concurrently) and use of medication in the following classes: tricyclic antidepressants, antihistamines, antiemetics, antipsychotics, antispasmotics, muscle relaxants, benzodiazepines, hypnotics, and opioids. The CRN confirms prescriptions with the patient. The CRN reports the medication risk in her provider report and provides medication management educational materials to the patient. At the patient's upcoming primary care visit, providers evaluated whether the medications associated with increased fall risk could be adjusted.
Study: NCT04068805

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.